METRO, GIULIO
METRO, GIULIO
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series
2016 Metro, Giulio; Lunardi, Gianluigi; Bennati, Chiara; Chiarini, Pietro; Sperduti, Isabella; Ricciuti, Biagio; Marcomigni, Luca; Costa, Cinzia; Crino', Lucio; Floridi, Piero; Gori, Stefania; Chiari, Rita
Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients.
2018 Metro, G; Giannarelli, D; Sidoni, A; Chiari, R; Bellezza, G
Assessment of TILs, IDO-1 and PD-L1 in resected non small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
2018 Mandarano, M; Bellezza, G; Belladonna, Ml; Van den Eynde, Bj; Chiari, R; Vannucci, J; Mondanelli, G; Ludovini, V; Ferri, I; Bianconi, F; Del Sordo, R; Cagini, L; Albini, E; Metro, G; Puma, F; Sidoni, A
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications
2019 Mandarano, Martina; Bellezza, Guido; Belladonna, Maria Laura; J Van den Eynde, Benoit; Chiari, Rita; Vannucci, Jacopo; Mondanelli, Giada; Ludovini, Vienna; Ferri, Ivana; Bianconi, Fortunato; DEL SORDO, Rachele; Cagini, Lucio; Albini, Elisa; Metro, Giulio; Puma, Francesco; Sidoni, Angelo
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option
2019 Ricciuti, B.; Lamberti, G.; Roila, F.; Metro, G.
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
2018 Metro, Giulio; Passaro, Antonio; Lo Russo, Giuseppe; Bonanno, Laura; Giusti, Raffaele; Gregorc, Vanesa; Capelletto, Enrica; Martelli, Olga; Cecere, Fabiana L; Giannarelli, Diana; Luciani, Andrea; Bearz, Alessandra; Tuzi, Alessandro; Scotti, Vieri; Tonini, Giuseppe; Galetta, Domenico; Carta, Annamaria; Soto Parra, Hector; Rebonato, Alberto; Morabito, Alessandro; Chiari, Rita
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
2020 Ricciuti, B.; Brambilla, M.; Cortellini, A.; De Giglio, A.; Ficorella, C.; Sidoni, A.; Bellezza, G.; Crino, L.; Ludovini, V.; Baglivo, S.; Metro, G.; Chiari, R.
CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles
2018 Rebonato, Alberto; Maiettini, Daniele; Andolfi, Marco; Fischer, Matthias J.; Vannucci, Jacopo; Metro, Giulio; Basile, Antonio; Rossi, Michele; Duranti, Michele
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr
2020 Siggillino, A.; Ulivi, P.; Pasini, L.; Reda, M. S.; Chiadini, E.; Tofanetti, F. R.; Baglivo, S.; Metro, G.; Crino, L.; Delmonte, A.; Minotti, V.; Roila, F.; Ludovini, V.
Early stage resectable non-small cell lung cancer: Is neoadjuvant immunotherapy the right way forward?
2018 Chiari, R.; Sidoni, A.; Metro, G.
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50%
2020 Metro, G.; Banna, G. L.; Signorelli, D.; Gili, A.; Galetta, D.; Galli, G.; Economopoulou, P.; Roila, F.; Friedlaender, A.; Camerini, A.; Christopoulou, A.; Cantale, O.; De Toma, A.; Pizzutilo, P.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Giannarelli, D.; Mountzios, G.; Addeo, A.
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?
2018 De Giglio, Andrea; Porreca, Roberta; Brambilla, Marta; Metro, Giulio; Prosperi, Enrico; Bellezza, Guido; Pirro, Matteo; Chiari, Rita; Ricciuti, Biagio
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis
2016 Ludovini, Vienna; Bianconi, Fortunato; Siggillino, Annamaria; Piobbico, Danilo; Vannucci, Jacopo; Metro, Giulio; Chiari, Rita; Bellezza, Guido; Puma, Francesco; Della Fazia, Maria Agnese; Servillo, Giuseppe; Crino', Lucio
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
2021 Ludovini, V.; Bianconi, F.; Siggillino, A.; Vannucci, J.; Baglivo, S.; Berti, V.; Tofanetti, F. R.; Reda, M. S.; Bellezza, G.; Mandarano, M.; Belladonna, M. L.; Metro, G.; Chiari, R.; Sidoni, A.; Puma, F.; Minotti, V.; Roila, F.
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy
2021 Baglivo, S.; Bianconi, F.; Metro, G.; Gili, A.; Tofanetti, F. R.; Bellezza, G.; Ricciuti, B.; Mandarano, M.; Teti, V.; Siggillino, A.; Reda, M. S.; Chiari, R.; Pistola, L.; Sidoni, A.; Minotti, V.; Roila, F.; Ludovini, V.
How might treatment of ALK-positive non-small cell lung cancer change in the near future?
2016 Metro, Giulio; Bellezza, Guido; Puma, Francesco; Chiari, Rita
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib
2018 Ricciuti, B; Marcomigni, L; Metro, G; Bellezza, G; Caselli, E; Baglivo, S; Chiari, R.
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
2021 Metro, G.; Signorelli, D.; Pizzutilo, E. G.; Giannetta, L.; Cerea, G.; Garaffa, M.; Friedlaender, A.; Addeo, A.; Mandarano, M.; Bellezza, G.; Roila, F.
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab
2020 Friedlaender, A.; Metro, G.; Signorelli, D.; Gili, A.; Economopoulou, P.; Roila, F.; Banna, G.; De Toma, A.; Camerini, A.; Christopoulou, A.; Lo Russo, G.; Banini, M.; Galetta, D.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Mountzios, G.; Garassino, M. C.; Addeo, A.
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool
2020 Mandarano, M.; Bellezza, G.; Belladonna, M. L.; Vannucci, J.; Gili, A.; Ferri, I.; Lupi, C.; Ludovini, V.; Falabella, G.; Metro, G.; Mondanelli, G.; Chiari, R.; Cagini, L.; Stracci, F.; Roila, F.; Puma, F.; Volpi, C.; Sidoni, A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series | 2016 | Metro, Giulio; Lunardi, Gianluigi; Bennati, Chiara; Chiarini, Pietro; Sperduti, Isabella; Ricciuti, Biagio; Marcomigni, Luca; Costa, Cinzia; Crino', Lucio; Floridi, Piero; Gori, Stefania; Chiari, Rita | |
| Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. | 2018 | Metro, G; Giannarelli, D; Sidoni, A; Chiari, R; Bellezza, G | |
| Assessment of TILs, IDO-1 and PD-L1 in resected non small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. | 2018 | Mandarano, M; Bellezza, G; Belladonna, Ml; Van den Eynde, Bj; Chiari, R; Vannucci, J; Mondanelli, G; Ludovini, V; Ferri, I; Bianconi, F; Del Sordo, R; Cagini, L; Albini, E; Metro, G; Puma, F; Sidoni, A | |
| Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications | 2019 | Mandarano, Martina; Bellezza, Guido; Belladonna, Maria Laura; J Van den Eynde, Benoit; Chiari, Rita; Vannucci, Jacopo; Mondanelli, Giada; Ludovini, Vienna; Ferri, Ivana; Bianconi, Fortunato; DEL SORDO, Rachele; Cagini, Lucio; Albini, Elisa; Metro, Giulio; Puma, Francesco; Sidoni, Angelo | |
| Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option | 2019 | Ricciuti, B.; Lamberti, G.; Roila, F.; Metro, G. | |
| Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | 2018 | Metro, Giulio; Passaro, Antonio; Lo Russo, Giuseppe; Bonanno, Laura; Giusti, Raffaele; Gregorc, Vanesa; Capelletto, Enrica; Martelli, Olga; Cecere, Fabiana L; Giannarelli, Diana; Luciani, Andrea; Bearz, Alessandra; Tuzi, Alessandro; Scotti, Vieri; Tonini, Giuseppe; Galetta, Domenico; Carta, Annamaria; Soto Parra, Hector; Rebonato, Alberto; Morabito, Alessandro; Chiari, Rita | |
| Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer | 2020 | Ricciuti, B.; Brambilla, M.; Cortellini, A.; De Giglio, A.; Ficorella, C.; Sidoni, A.; Bellezza, G.; Crino, L.; Ludovini, V.; Baglivo, S.; Metro, G.; Chiari, R. | |
| CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles | 2018 | Rebonato, Alberto; Maiettini, Daniele; Andolfi, Marco; Fischer, Matthias J.; Vannucci, Jacopo; Metro, Giulio; Basile, Antonio; Rossi, Michele; Duranti, Michele | |
| Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr | 2020 | Siggillino, A.; Ulivi, P.; Pasini, L.; Reda, M. S.; Chiadini, E.; Tofanetti, F. R.; Baglivo, S.; Metro, G.; Crino, L.; Delmonte, A.; Minotti, V.; Roila, F.; Ludovini, V. | |
| Early stage resectable non-small cell lung cancer: Is neoadjuvant immunotherapy the right way forward? | 2018 | Chiari, R.; Sidoni, A.; Metro, G. | |
| Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% | 2020 | Metro, G.; Banna, G. L.; Signorelli, D.; Gili, A.; Galetta, D.; Galli, G.; Economopoulou, P.; Roila, F.; Friedlaender, A.; Camerini, A.; Christopoulou, A.; Cantale, O.; De Toma, A.; Pizzutilo, P.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Giannarelli, D.; Mountzios, G.; Addeo, A. | |
| Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? | 2018 | De Giglio, Andrea; Porreca, Roberta; Brambilla, Marta; Metro, Giulio; Prosperi, Enrico; Bellezza, Guido; Pirro, Matteo; Chiari, Rita; Ricciuti, Biagio | |
| Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis | 2016 | Ludovini, Vienna; Bianconi, Fortunato; Siggillino, Annamaria; Piobbico, Danilo; Vannucci, Jacopo; Metro, Giulio; Chiari, Rita; Bellezza, Guido; Puma, Francesco; Della Fazia, Maria Agnese; Servillo, Giuseppe; Crino', Lucio | |
| High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients | 2021 | Ludovini, V.; Bianconi, F.; Siggillino, A.; Vannucci, J.; Baglivo, S.; Berti, V.; Tofanetti, F. R.; Reda, M. S.; Bellezza, G.; Mandarano, M.; Belladonna, M. L.; Metro, G.; Chiari, R.; Sidoni, A.; Puma, F.; Minotti, V.; Roila, F. | |
| Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy | 2021 | Baglivo, S.; Bianconi, F.; Metro, G.; Gili, A.; Tofanetti, F. R.; Bellezza, G.; Ricciuti, B.; Mandarano, M.; Teti, V.; Siggillino, A.; Reda, M. S.; Chiari, R.; Pistola, L.; Sidoni, A.; Minotti, V.; Roila, F.; Ludovini, V. | |
| How might treatment of ALK-positive non-small cell lung cancer change in the near future? | 2016 | Metro, Giulio; Bellezza, Guido; Puma, Francesco; Chiari, Rita | |
| Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib | 2018 | Ricciuti, B; Marcomigni, L; Metro, G; Bellezza, G; Caselli, E; Baglivo, S; Chiari, R. | |
| Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma | 2021 | Metro, G.; Signorelli, D.; Pizzutilo, E. G.; Giannetta, L.; Cerea, G.; Garaffa, M.; Friedlaender, A.; Addeo, A.; Mandarano, M.; Bellezza, G.; Roila, F. | |
| Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab | 2020 | Friedlaender, A.; Metro, G.; Signorelli, D.; Gili, A.; Economopoulou, P.; Roila, F.; Banna, G.; De Toma, A.; Camerini, A.; Christopoulou, A.; Lo Russo, G.; Banini, M.; Galetta, D.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Mountzios, G.; Garassino, M. C.; Addeo, A. | |
| Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool | 2020 | Mandarano, M.; Bellezza, G.; Belladonna, M. L.; Vannucci, J.; Gili, A.; Ferri, I.; Lupi, C.; Ludovini, V.; Falabella, G.; Metro, G.; Mondanelli, G.; Chiari, R.; Cagini, L.; Stracci, F.; Roila, F.; Puma, F.; Volpi, C.; Sidoni, A. |